If you have been reading about lipolysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
During this period, Aden became important for British military and commercial purposes in the region, as well as a base for the Royal Navy and the Royal Air Force. The colony's surrounding hinterland, was governed separately as the Aden Protectorate. By the early 1960s, widespread dissatisfaction with British rule led to the Aden Emergency, a violent uprising against colonial authorities. In 1963, Aden Colony was reconstituted as the State of Aden within the newly created Federation of South Arabia in an attempt to grant limited self-governance, but the unrest continued. The British withdrew in 1967, and the colony was succeeded by the People's Republic of Southern Yemen, marking the end of British control after 128 years of rule.
Retinol is chemically unstable in topical formulations and is sensitive to factors such as light, oxygen, heat, and heavy metals; formulation approaches including retinol derivatives, antioxidants, chelating agents, and lipid-based or nanoformulation systems have been investigated to improve stability, tolerability, and skin delivery. A common side effect of topical retinoid therapy is "retinoid dermatitis", irritation or reaction characterized by erythema, scaling, dryness, and pruritis. Topical retinol has been regulated as a cosmetic ingredient in the European Union and UK since November 2025; under Commission Regulation 2024/996, retinol was limited to a maximum of 0.05% retinol equivalent in body lotion and 0.3% in other leave-on and rinse-off products, with mandatory labelling.
In October 1969, Willy Brandt became chancellor. He maintained West Germany's close alignment with the United States and focused on strengthening European integration in western Europe, while launching the new policy of Ostpolitik aimed at improving relations with Eastern Europe. Brandt was controversial on both the right wing, for his Ostpolitik, and on the left wing, for his support of right-wing authoritarian regimes and of American policies, including the Vietnam War. The Brandt Report became a recognised measure for describing the general North-South divide in world economics and politics between an affluent North and a poor South. Brandt was also known for his fierce anti-communist policies at the domestic level, culminating in the Radikalenerlass (Anti-Radical Decree) in 1972. In 1970, while visiting a memorial to the Warsaw Ghetto Uprising crushed by the Germans, Brandt unexpectedly knelt and meditated in silence, a moment remembered as the Kniefall von Warschau. Brandt resigned as chancellor in 1974, after Günter Guillaume, one of his closest aides, was exposed as an agent of the Stasi, the East German secret service.
Sources: en.wikipedia.org
== Awards and decorations == For his commitment in Asian countries Prof. Rode has received many awards, amongst others the Honorary Doctorate Degree in Sciences of the Chulalongkorn University, Bangkok (1995), the Honorary Doctorate Degree in Sciences of the King Mongkut’s Institute of Technology, Ladkrabang, Bangkok (1998) and the Honorary Doctorate Degree in Sciences of the Gadjah Mada University, Yogyakarta, Indonesia (2000). In 2007 the King of Thailand, awarded Prof. Rode with the Knight Grand Cross (First Class), the Most Noble Order of the Crown of Thailand, for his activities and achievements to intensify the European-Asian scientific collaborations. In 2008 the Comenius University Bratislava awarded him an Honorary Doctorate Degree for his pioneer work in quantum chemistry studies of molecule and super molecule systems of ion solvation and molecular modelling of biomolecules and medicaments. In 2014 he was appointed Honorary President of ASEA-UNINET. Overview most important Awards and Decorations:
=== Quantum mechanics effects === Quantum mechanics effects become noticeable for nanoscale objects. They include quantum confinement in semiconductor particles, localized surface plasmons in some metal particles, and superparamagnetism in magnetic materials. Quantum dots are nanoparticles of semiconducting material that are small enough (typically sub 10 nm or less) to have quantized electronic energy levels. Quantum effects are responsible for the deep-red to black color of gold or silicon nanopowders and nanoparticle suspensions. Absorption of solar radiation is much higher in materials composed of nanoparticles than in thin films of continuous sheets of material. In both solar PV and solar thermal applications, by controlling the size, shape, and material of the particles, it is possible to control solar absorption. Core-shell nanoparticles can support simultaneously both electric and magnetic resonances, demonstrating entirely new properties when compared with bare metallic nanoparticles if the resonances are properly engineered. The formation of the core-shell structure from two different metals enables an energy exchange between the core and the shell, typically found in upconverting nanoparticles and downconverting nanoparticles, and causes a shift in the emission wavelength spectrum. By introducing a dielectric layer, plasmonic core (metal)-shell (dielectric) nanoparticles enhance light absorption by increasing scattering.
The pH of an electrophoretic gel is determined by the buffer used for that gel. If the pH of the buffer is above the pI of the protein being run, the protein will migrate to the positive pole (negative charge is attracted to a positive pole). If the pH of the buffer is below the pI of the protein being run, the protein will migrate to the negative pole of the gel (positive charge is attracted to the negative pole). If the protein is run with a buffer pH that is equal to the pI, it will not migrate at all. This is also true for individual amino acids.
The word metagenics uses the prefix meta and the suffix gen. Literally, it means "the creation of something which creates". In the context of biotechnology, metagenics is the practice of engineering organisms to create a specific enzyme, protein, or other biochemical from simpler starting materials. The genetic engineering of E. coli with the specific task of producing human insulin from starting amino acids is an example. E. coli has also been engineered to digest plant biomass and use it to produce hydrocarbons in order to synthesize biofuels. The applications of metagenics on E. coli also include higher alcohols, fatty-acid based chemicals and terpenes.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.